After 5 years, pembrolizumab plus pemetrexed-platinum was associated with improved overall survival (OS) and progression-free survival compared with placebo plus pemetrexed-platinum in patients with ...

They evaluated pembrolizumab in patients with resectable stage II-IV (M0) cSCC. Patients received 200 mg pembrolizumab every 3 weeks for 4 cycles, followed by 18F-labeled fluorodeoxyglucose-positron ...

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 melanoma improved event-free survival compared with adjuvant therapy alone.

Pembrolizumab is also approved as first-line treatment in cisplatin-ineligible patients with high PD-L1 expression. 9 - 11 Integrating short courses of pre-RC immunotherapy in nonmetastatic MIBC has ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma ...

The addition of pembrolizumab to chemotherapy improved OS, PFS and objective response rates among patients with untreated, advanced esophageal and esophagogastric junction adenocarcinoma, results ...